Loading...
•
Sep 30, 2021
Repare Therapeutics Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Key Takeaways
Repare Therapeutics reported initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference, demonstrating a favorable safety profile and promising early activity for RP-3500. The company raised gross proceeds of $101.2 million in an upsized follow-on public offering and appointed Thomas Civik as the new Chairman of the Board. Net loss for the quarter was $30.9 million, or $0.83 per share.
Announced initial monotherapy clinical data from Phase 1/2 TRESR study of RP-3500 in patients with solid tumors at the AACR-NCI-EORTC conference.
Raised Gross Proceeds of $101.2 Million in Upsized Follow-on Public Offering.
Appointed Thomas Civik to Board of Directors as new Chairman.
Achieved $0.9 million (¥100 million) research trigger pursuant to the terms of its research services, license and collaboration agreement with Ono Pharmaceutical Co., Ltd
Forward Guidance
Final readouts from patients enrolled in the monotherapy arm of the TRESR trial, as well as initial data from the combination arm testing RP-3500 together with PARP inhibitors, are expected in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...